Area of research
Genetics · Hematology
Research interest
Research interests include Medicine, Internal medicine, Myelofibrosis, Polycythemia vera, Essential thrombocythemia, and Ruxolitinib.
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up
Cerebral vein thrombosis in patients with <scp>P</scp>hiladelphia‐negative myeloproliferative neoplasms An <scp>E</scp>uropean <scp>L</scp>eukemia <scp>N</scp>et study
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Mutations and prognosis in primary myelofibrosis
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs